Your search for bevacizumab returned 122 results

Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab

The conversion from provisional to full approval was based on totality of evidence of Avastin in glioblastoma.

However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

Data from a Phase 1/2 study in patients with MDS who had disease progression on or after first-line azacitidine treatment showed initial signs of clinical activity with DSP-7888, and that it was well tolerated in study patients.

Medications can induce HTN through a variety of mechanisms such as volume retention, sympathomimetic activation, and direct vasoconstriction.

Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).

To reduce the risk or slow the progression of of diabetic retinopathy, the guidelines recommend optimizing glycemic control, as well as lowering blood pressure and serum lipids.

Progression-free survival down with antibiotic use for patients receiving immune checkpoint inhibitors

Genentech announced that the Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin alone, for the treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.